Early switch and early discharge strategies in patients with community-acquired pneumonia: A meta-analysis

Archives of Internal Medicine

Volumn 161, Issue 5, 2001, Pages 722-727

  Rhew, David C ^a,c   Tu, George S ^a,b   Ofman, Joshua ^a,b   Henning, James M ^d   Richards, Margaret S ^d   Weingarten, Scott R ^a,b  

^a Zynx Health   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; DATA BASE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; META ANALYSIS; OUTCOMES RESEARCH; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0035848337     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.5.722     Document Type: Article

References (16)

1. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio
2. The cost of treating patients with community-acquired pneumonia
3. Early switch from intravenous to oral antibiotics and early hospital discharge: A prospective observational study of 200 consecutive patients with community-acquired pneumonia
4. Variation in length of hospital stay in patients with community-acquired pneumonia: Are snorter stays associated with worse medical outcomes?
5. Some statistical methods for combining experimental results
6. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
7. Switch therapy with beta-lactam/beta-lactamase inhibitors in patients with community-acquired pneumonia
8. Early transition to oral antibiotic therapy for community-acquired pneumonia, duration of therapy, clinical outcomes, an d cost analysis
9. A prospective, multicenter study of a pneumonia practice guideline
10. Evaluation of a critical pathway for pneumonia
11. Evaluation of a pneumonia practice guideline in an interventional trial
12. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia
13. Pharmacoeconomic benefit of antibiotic step-down therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil
14. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia the optimal duration of therapy